Acurx Pharmaceuticals, Inc. (ACXP)
| Market Cap | 7.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.97M |
| Shares Out | 3.67M |
| EPS (ttm) | -5.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,376 |
| Open | 1.990 |
| Previous Close | 2.030 |
| Day's Range | 1.980 - 2.130 |
| 52-Week Range | 1.326 - 21.000 |
| Beta | -1.92 |
| Analysts | Strong Buy |
| Price Target | 95.50 (+4,675.0%) |
| Earnings Date | May 12, 2026 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant e... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ACXP stock is "Strong Buy." The 12-month stock price target is $95.5, which is an increase of 4,675.00% from the latest price.
News
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new clas...
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac...
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Ac...
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu...
Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025
Ibezapolstat advanced with strong phase II results and a new rCDI trial launching in late 2026, supported by improved financials and a strengthened patent position. Lower expenses and ongoing funding initiatives position the company for pivotal trials and potential regulatory acceleration.
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor react...
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial with ibezapolstat in patients wit...
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics f...
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule...
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the mo...
Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw improved financials with reduced losses and increased cash, driven by cost controls and new capital. Regulatory and partnership progress continues for ibezapolstat, with key scientific milestones and expanded IP. Major partnership news may be forthcoming.
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, MRSA, ...
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC inhibitor, ibezapolstat (IBZ), has unique selective antibacterial activity in the gut which spares beneficial bile acid-...
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y. , Oct. 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecul...
Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infection Re...
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
Acurx Maintains Listing on the Nasdaq STATEN ISLAND, N.Y. , Sept. 3, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company ...
Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 saw improved financials with reduced losses and expenses, successful capital raises, and positive clinical progress for ibezapolstat. Strategic partnerships and cost control remain priorities as the company advances toward phase III trials.
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
STATEN ISLAND, N.Y. , Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025 STATEN ISLAND, N.Y. , July 31, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur...
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y. , June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...